JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of… read more.
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of Voquezna (vonoprazan)… read more.
Merck, known as MSD outside of the United States and Canada, and Eisai announced the FDA has approved the dual oral regimen of WELIREG (belzutifan), Merck’s first-in-class oral… read more.
Eli Lilly and Company announced that the FDA approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe… read more.
Eli Lilly and Company announced the FDA approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults… read more.
Eli Lilly and Company announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater… read more.
Pharming announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja (leniolisib), an oral,… read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10μg)) has been approved in the European Union (EU) as a maintenance treatment for asthma in patients 12… read more.
AbbVie announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September… read more.
Lantheus Holdings announced that the FDA has granted final approval for Bravnetsa (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera (lutetium Lu 177 dotatate)…. read more.
AbbVie announced that the European Commission (EC) has approved Rinvoq (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic… read more.
Zealand Pharma A/S announces the initiation of the global registrational Phase 3 Zupreme program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
